Prior to this study, explained researchers, data on the long-term course of osteoporosis, as evaluated through bone mineral density (BMD) in these patients, have been lacking.
Nearly half of patients with hemophilia have decreased bone mineral density (BMD), suggest study findings published in Hamostaseologie, which also showed that levels remain consistent throughout the course of the bleeding disorder. Prior to this study, explained the researchers, data on the long-term course of osteoporosis in these patients have been lacking.
Across the 33 adult patients in the retrospective study, 48.5% had osteopenia and 21.2% had osteoporosis at the last follow-up. In line with previous studies, the researchers observed lower vitamin D levels among their patients, suggesting that screening for the deficiency and supplementing with vitamin D may be warranted.
“In general, a vitamin D deficiency is a frequently mentioned influencing factor on BMD. With vitamin D being essential for the bone metabolism, a lack of it results in an increased risk for osteoporosis,” commented the researchers. “Within our cohort study, 78.8% of the patients suffered from a vitamin D deficiency (< 30 ng/mL). Kempton et al reported reduced vitamin D levels in one-third, up to one-half of the patients with hemophilia. By contrast, according to Rabenberg et al, only 38.4% adults in the standard German population (38.3% of all men) suffer from a vitamin D deficiency.”
Each patient received at least 2 bone density measurements with a minimum range of 10 years, with results not changing significantly from one point of time to the next. The researchers noted that because of the long observation period, not all dual-energy x-ray absorptiometry scans were performed with the same device.
Almost half of the patients received osteoporosis-based treatment, including vitamin D and calcium. However, receiving anti-osteoporotic treatment, whether basic or specific, was associated with a significant change in BMD.
Meanwhile, there was a significant positive correlation between body mass index and BMD and significant negative correlation between Gilbert score of joint health and t-score for bone density, the latter having been documented previously. Based on the finding, the researchers suggest practices consider using Gilbert score for pre-estimating the benefit of a more invasive osteoporosis diagnostic approach.
“Consumption of nicotine and alcohol, despite being well-known risk factors for osteoporosis, did not affect bone mass in a statistically significant way,” explained the researchers. “This is also true for our patients’ most frequent comorbidities such as hypertension, type 2 diabetes, dyslipidemia, and liver cirrhosis. Even repetitive local or systemic cortisone therapy did not affect patients’ BMD in the course of time.”
Morbidity rating also showed no effect on bone mass.
Based on their findings, the researchers flagged a need for further research to assess the reason for osteopenia in patients with hemophilia.
Reference
Strauss A, Muellejans P, Koob S, et al. Osteoporosis remains constant in patients with hemophilia—long-term course in consideration of comorbidities. Hamostaseologie. Published online March 2, 2023. doi:10.1055/a-1972-8983
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More